Dactinomycin adverse effects

Adverse effects The major dose-limiting toxicity is bone marrow depression, and the drug is immunosuppressive. Other adverse reactions include nausea, vomiting, diarrhea, stomatitis, and alopecia. Extravasation during injection produces serious problems. Dactinomycin sensitizes to radiation inflammation at sites of prior radiation therapy may occur. 

Adverse effects Irreversible, dose-dependent cardiotoxicity, apparently a result of the generation of free radicals, is the most serious adverse reaction. Irradiation of the thorax increases the risk of cardiotoxicity. There has been some success with the iron chelator, dexrazone, in protecting against the cardiotoxicity of doxorubicin. As with dactinomycin, both doxorubicin and daunorubicin also cause a transient bone marrow suppression, stomatitis, and Gl tract disturbances. Alopecia is usually severe. 

Dactinomycin is nsed to treat cancers in children, in par-ticnlar Wilms tnmor. It has similar adverse effects to doxombicin. 

Adverse effects of dactinomycin, which begin 3 to 4 days after initiation of therapy, include cheilitis, dysphagia. 

Pacific Northwest.) Encyclopedic references comment that the antibiotics doxorubicin, daunorubicin, bleomycin, mitomycin, and dactinomycin are all antineoplastic or anticancer agents, but are mostly too toxie for antibiotic use (and perhaps are too toxic to be used as anticancer agents, a ease again of adverse side effects). 

---